+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 70Years
All Genders
ID06658522

Study of Sotatercept to Improve Right Heart Function in Adults with Pulmonary Arterial Hypertension

Led by Amsterdam UMC, location VUmc · Updated on 2025-09-22

20

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Pulmonary arterial hypertension PAH is a progressive condition marked by changes in the blood vessels leading to high pressure in the pulmonary artery, eventually causing severe right heart failure. Current treatments mainly focus on medications that widen blood vessels but do not address the underlying vessel changes. Sotatercept is a new medication being studied that targets specific pathways to restore balance and counteract these vessel changes, potentially improving heart function more effectively than traditional treatments. In this open-label, phase 4 study, participants with PAH will receive subcutaneous injections of sotatercept starting at 0.3 mgkg, with the possibility to increase to 0.7 mgkg based on blood test results. The treatment lasts for 24 weeks, during which participants visit the hospital every three weeks for blood tests, physical exams, and monitoring for any side effects. Before starting and after completing treatment, detailed heart assessments including right heart catheterization and cardiac magnetic resonance imaging are performed to evaluate heart function and structure. Participants will be involved in regular assessments such as physical exams, blood draws, a six-minute walk test to measure exercise capacity, and advanced heart imaging to track changes in heart function and fibrosis. Researchers will closely monitor cardiac work and coupling, as well as volumes and mass of both right and left ventricles. The study includes a 5-week follow-up after treatment ends to ensure safety and observe any lasting effects, with total participation spanning approximately 29 weeks from screening through follow-up.

CONDITIONS

Brief Title

Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)

Research Team

H

Harm Jan Bogaard, M.D., PhD

E

Eszter N Toth, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here